Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 463-470

  Sonmez, Osman ^a   Ertem, Furkan U ^b   Vatankulu, Mehmet Akif ^a   Erdogan, Ercan ^a   Tasal, Abdurrahman ^a   Kucukbuzcu, Sitki ^a   Goktekin, Omer ^a  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Atrial fibrillation; Atrial remodeling; Collagen type III; Galectin 3; Lipocalins; Matrix metalloproteinase 9

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GALECTIN 3; GELATINASE B; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BODY MASS; BODY SURFACE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART STROKE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; SINUS RHYTHM; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; ATRIAL REMODELING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTROCARDIOGRAPHY; FEMALE; FIBROSIS; HEART VALVES; HUMANS; INFLAMMATION; LIPOCALINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROTO-ONCOGENE PROTEINS;

EID: 84897902841     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890635     Document Type: Article

References (40)

1. Jauch EC, Saver JL, Adams HP Jr et al: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013; 44: 870-947
2. Lip GY, Patel JV, Hughes E, Hart RG: High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke, 2007; 38: 1229-37
3. Gramley F, Lorenzen J, Plisiene J et al: Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol, 2007; 18: 1076-82
4. Kalogeropoulos AS, Tsiodras S, Rigopoulos AG et al: Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord, 2011; 11: 77
5. Gai X, Lan X, Luo Z et al: Association of MMP-9 gene polymorphisms with atrial fibrillation in hypertensive heart disease patients. Clin Chim Acta, 2009; 408: 105-59
6. Licata G, Tuttolomondo A, Di Raimondo D et al: Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost, 2009; 101: 929-37
7. Ehrlich JR, Kaluzny M, Baumann S et al: Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol, 2011; 100: 1029-36
8. Pena JM, MacFadyen J, Glynn RJ, Ridker PM: High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J, 2012; 33: 531-37
9. Ertas G, Sonmez O, Turfan M et al: Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. J Neurol Sci, 2013; 324: 49-52
10. Aribas A, Akilli H, Gul EE et al: Can neutrophil/lymphocyte ratio predict recurrence of non-valvular atrial fibrillation after cardioversion? Anadolu Kardiyol Derg, 2013; 13: 123-30
11. Bhat T, Teli S, Rijal J et al: Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther, 2013; 11: 55-59
12. McCullough PA, Olobatoke A, Vanhecke TE: Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med, 2011; 12: 200-10
13. Gruson D, Ko G: Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem, 2012; 45: 719-26
14. Lok DJ, Van Der Meer P, de la Porte PW et al: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010; 99: 323-28
15. Vanhoutte PM: [Endothelial dysfunction in obesity]. Ann Pharm Fr, 2013; 71: 42-50
16. Ding L, Hanawa H, Ota Y et al: Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J, 2010; 74: 523-30
17. Choi KM, Lee JS, Kim EJ et al: Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol, 2008; 158: 203-7
18. Diez J, Laviades C, Mayor G et al: Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation, 1995; 91: 1450-56
19. Dellegrottaglie S, Sands RL, Gillespie BW et al: Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD study. Nephrol Dial Transplant, 2011; 26: 2891-98
20. Gluba A, Bielecka A, Mikhailidis DP et al: An update on biomarkers of heart failure in hypertensive patients. J Hypertens, 2012; 30: 1681-89
21. Schiller NB, Shah PM, Crawford M et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr, 1989; 2: 358-67
22. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation, 1977; 55: 613-18
23. Staszewsky L, Wong M, Masson S et al: Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy. Circ Cardiovasc Imaging, 2011; 4: 721-28
24. Zhu H, Zhang W, Guo CH et al: [Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation]. Zhonghua Yi Xue Za Zhi, 2005; 85: 45-48
25. Zhao Y, Zhou X, Liao X, Yang Z: [Expression and significance of matrix metalloproteinase- 1,9, tissue inhibitor of metalloproteinase-4 and extracellular matrix metalloproteinase inducer in the myocardium of congestive heart failure in patients with rheumatic heart diseases]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2009; 34: 790-95
26. Lin YH, Lin LY, Wu YW et al: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta, 2009; 409: 96-99
27. Park M, Sweeney G: Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev. 2013; 18(5): 631-44
28. Fassett RG, Robertson IK, Ball MJ et al: Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrol Dial Transplant, 2012; 27: 182-89
29. Romero JR, Vasan RS, Beiser AS et al: Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study. J Stroke Cerebrovasc Dis, 2008; 17: 412-17
30. Swartz MF, Fink GW, Sarwar MF et al: Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol, 2012; 60(18): 1799-806
31. Edwards NC, Ferro CJ, Kirkwood H et al: Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol, 2010; 106: 1505-11
32. Udelson JE, Feldman AM, Greenberg B et al: Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail, 2010; 3: 347-53
33. Sahin T, Acar E, Celikyurt U et al: Relation of hs-CRP and BNP levels with the atrial spontaneous echo contrast and thrombi in permanent atrial fibrillation patients with different etiologies. Med Sci Monit, 2012; 18 (2): CR78-87
34. Canpolat U, Aytemir K, Yorgun H et al: Role of Preablation Neutrophil/ Lymphocyte Ratio on Outcomes of Cryoballoon-Based Atrial Fibrillation Ablation. Am J Cardiol, 2013; pii: S0002-9149(13)00989-2
35. Goette A, Staack T, Rocken C et al: Increased expression of extracellular signal- regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol, 2000; 35: 1669-77
36. Zhang Y, Zhang P, Mu Y et al: The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther, 2010; 88: 521-31
37. Durin O, Pedrinazzi C, Inama G: Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results. J Cardiovasc Med (Hagerstown), 2010; 11: 912-18
38. Sasamura H, Kitamura Y, Nakamura M et al: Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens, 2006; 28: 511-20
39. Yoon N, Cho JG, Kim KH et al: Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. Exp Ther Med, 2013; 5: 1009-16
40. Camm AJ, Al-Khatib SM, Calkins H et al: A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J, 2013; 164: 292-302